目的探讨中心静脉狭窄/闭塞透析患者经皮腔内球囊扩张术(percutaneous transluminal angioplasty，PTA)或支架置入术(percutaneous transluminal stenting，PTS)的远期通畅率及治疗费用。方法对我中心于行PTA 或PTS 患者进行回顾性分析。结果单纯PTA 3，6，12，24 月初级通畅率为88.2%，73.3%，57.1%，37.5%，次级通畅率为94.1%, 86.7%, 71.4%, 50.0%；PTA+PTS 3，6，12，24 月初级通畅率为88.9%，66.7%，33.3%，0%，次级通畅率为100%，83.3%，66.7%，33.3%。首次PTA 平均费用为20 938.50 元，首次PTS 平均费用为32 599.58 元。结论目前介入治疗费用较高，远期通畅率仍有赖于技术发展获取进一步提升。

Objective To investigate the long-term patency and the expense of the percutaneous transluminal angioplasty (PTA) and stentin (PTS) for central vene stenosis (CVS) in maintenance hemodialysis patients. Methods We retrospectively analyzed the patients receiving PTA or PTS in our center. Results the primary patency rates after PTA for 3, 6, 12 and 24 months were 88.2%, 73.3%, 57.1% and 37.5% respectively, and the secondary patency rates were 94.1%, 86.7%, 71.4% and 50.0% respectively. The primary patency rates after PTA+PTS for 3, 6, 12 and 24 months were 88.9%, 66.7%, 33.3% and 0% respectively, and the secondary
patency rates were 100%, 83.3%, 66.7% and 33.3% respectively. The average expense for the first PTA was 2,0938.50 yuan, and the average expense for the first PTS was 3,2599.58 yuan. Conclusion Currently, the endovascular interventional treatment for CVS is expensive. The long-term patency still depends on the development of advanced technology and devices.